- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03166527
Panzyga in CIDP Administered at Different Infusion Rates (Panzyga-CIDP)
Prospective, Open-Label, Phase IIIb Study Evaluating the Safety, Tolerability and Efficacy of Panzyga® in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Administered at Standard and High Infusion Rates
Study Overview
Status
Intervention / Treatment
Detailed Description
The proposed trial will be an exploratory, open-label, single-centre, phase IIIb safety, tolerability and efficacy study, wherein each patient acts as their own control. The primary outcome measure is safety and tolerability of panzyga in patients with active CIDP at standard and high infusion rates as measured by:
- Occurrence of all adverse events with focus on adverse drug reactions (ADRs)
- The secondary outcomes include: Patients' treatment satisfaction, proportion of patients successfully achieving higher infusion rates, health utilities associated with treatment, proportion of responders to treatment based on change in clinical scores, grip strength, and quality of life measures. The total sample size is 25-30 patients, based on a difference of 30% in adverse events rates between the standard infusion rate and the maximum rate tolerated by each patient.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2C4
- UHNToronto
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with diagnosis of definite or probable CIDP according to the EFNS/PNS Guideline 2010; including patients with Multifocal Acquired Demyelinating Sensory And Motor Neuropathy (MADSAM) or pure motor CIDP
- Patients with active disease, i.e. not being in remission.
- IVIG naïve patients with clinical indication for IVIG based on progressive or relapsing disease and adjusted INCAT (ONLS) disability score between 2 and 9 (with a score of 2 coming exclusively from leg disability).
- Patients already receiving IVIG must be on 3- or 4-weekly IVIG treatment schedule with a calculated monthly dosage between 0.8 g/kg and 2.0 g/kg BW
- ≥ 18 years of age
- Voluntarily given, fully informed written consent obtained from patient before any study-related procedures are conducted
- For enrolment into the Second Phase: At each of the last three infusions in the First Phase, administration of panzyga® had to be at the maximum infusion rate of 0.08 mL/kg/min and good tolerated- assessment by Investigator according to local site practice
Exclusion Criteria:
- MMN with conduction block
- Patients who previously failed immunoglobulin therapy
- Treatment with immunomodulatory/suppressive agents (cyclosporin, methotrexate, mitoxantrone, mycophenolate mofetil or azathioprine) during the six months prior to baseline visit
- Patients on or treated with rituximab, alemtuzumab, cyclophosphamide, or other intensive chemotherapeutic regimens, previous lymphoid irradiation or stem cell transplantation during the 12 months prior to baseline visit
- Respiratory impairment requiring mechanical ventilation
- Myelopathy or evidence of central nervous system demyelination or significant persisting neurological deficits from stroke, or central nervous system (CNS) trauma
Clinical evidence of peripheral neuropathy from another cause such as
- connective tissue disease or systemic lupus erythematosus (SLE)
- HIV infection, hepatitis, Lyme disease
- cancer (with the exception of basal cell skin cancer)
- IgM paraproteinemia with anti-myelin associated glycoprotein antibodies
- Diabetic neuropathy
- Cardiac insufficiency (New York Heart Association [NYHA] III/IV), cardiomyopathy, significant cardiac dysrhythmia requiring treatment, unstable or advanced ischemic heart disease
- Severe liver disease (ALAT 3x > normal value)
- Severe kidney disease (creatinine 1.5x > normal value)
- Hepatitis B, hepatitis C or HIV infection
- Thromboembolic events: patients with a history of deep vein thrombosis (DVT) within the last year prior to baseline visit or pulmonary embolism ever; patients with susceptibility to embolism or DVT
- Body mass index (BMI) ≥40 kg/m2
- Selective IgA deficiency with known anti-IgA antibodies
- History of hypersensitivity, anaphylaxis or severe systemic response to immuno-globulin, blood or plasma derived products, or any component of panzyga®
- Known blood hyperviscosity, or other hypercoagulable states
- Use of other blood or plasma-derived products within three months prior to enrolment
- Patients with a past or present history of drug abuse or alcohol abuse within the preceding five years prior to baseline visit
- Patients unable or unwilling to understand or comply with the study protocol
- Participation in another interventional clinical study with IMP treatment currently or during the three months prior to enrolment
- Women who are breast feeding, pregnant, or planning to become pregnant, or are unwilling to use an effective birth control method (such as implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs), sexual abstinence or vasectomized partner) while on study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Open Label study
open label study using Panzyga immune globulin 10% intravenous solution with no placebo.
|
standard Immune lobulin 10% intravenous solution infusion at standard and high infusion rates.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurrence of all adverse events with focus on adverse drug reactions (ADRs)
Time Frame: 2 years
|
adverse drug reactions
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
treatment satisfaction
Time Frame: 2 years
|
completion of questionnaire
|
2 years
|
proportion of patients successfully achieving higher infusion rates
Time Frame: 2 years
|
descriptive analysis of number of patients
|
2 years
|
health utilities
Time Frame: 2 years
|
completion of questionnaire
|
2 years
|
proportion of responders to treatment based on change in clinical scores
Time Frame: 2 years
|
completion of scale
|
2 years
|
grip strength
Time Frame: 2 years
|
measurements in kPa
|
2 years
|
quality of life measures
Time Frame: 2 years
|
completion of scale
|
2 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Immune System Diseases
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Neuromuscular Diseases
- Peripheral Nervous System Diseases
- Polyradiculoneuropathy
- Polyneuropathies
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Physiological Effects of Drugs
- Immunologic Factors
- Antibodies
- Immunoglobulins
- Immunoglobulins, Intravenous
- gamma-Globulins
- Rho(D) Immune Globulin
Other Study ID Numbers
- 1001 (Registro Nacional Estudios Clinicos (RNEC))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
-
University of AarhusOdense University Hospital; Aarhus University Hospital; Rigshospitalet, Denmark; Aalborg University HospitalRecruitingCIDP - Chronic Inflammatory Demyelinating PolyneuropathyDenmark
-
University Hospital, BordeauxRecruitingChronic Inflammatory Demyelinating Polyneuropathy (CIDP)France
-
CSL BehringCompletedPolyradiculoneuropathy, Chronic Inflammatory Demyelinating | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)United States, Japan, Australia, Canada, Czechia, France, Germany, Italy, Netherlands, Spain, United Kingdom
-
UCB Biopharma SRLNo longer availableChronic Inflammatory Demyelinating Polyneuropathy (CIDP)
-
Oregon Health and Science UniversityCollins Medical TrustCompletedChronic Inflammatory Demyelinating Polyneuropathy | CIDPUnited States
-
CSL BehringRecruitingPediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)United States
-
argenxCompletedChronic Inflammatory Demyelinating Polyneuropathy (CIDP)United States, Austria, Belgium, Bulgaria, China, Czechia, Denmark, France, Georgia, Germany, Hungary, Israel, Italy, Japan, Latvia, Netherlands, Poland, Romania, Russian Federation, Serbia, Spain, Taiwan, Turkey, Ukraine, United Kingdom
-
argenxActive, not recruitingChronic Inflammatory Demyelinating Polyneuropathy (CIDP)United States, Austria, Belgium, Bulgaria, China, Czechia, Denmark, France, Georgia, Germany, Israel, Italy, Japan, Netherlands, Poland, Russian Federation, Serbia, Spain, Ukraine, United Kingdom, Latvia, Romania, Taiwan, Turkey
-
University of UlmMiltenyi Biomedicine GmbHRecruiting
-
Heinrich-Heine University, DuesseldorfActive, not recruiting
Clinical Trials on Immune Globulin 10% Intravenous Solution
-
Baxalta now part of ShireCompleted
-
Baxalta now part of ShireTerminatedAlzheimer´s DiseaseUnited States, Poland, United Kingdom, Belgium, Spain, Japan, Canada, Australia
-
Baxalta now part of ShireAlzheimer's Disease Cooperative Study (ADCS)CompletedAlzheimer´s DiseaseUnited States, Canada
-
Green Cross CorporationParexel; Atlantic Research GroupCompletedImmunologic Deficiency SyndromesCanada, United States
-
Inova Health Care ServicesCSL BehringWithdrawn
-
Prometic Biotherapeutics, Inc.Atlantic Research GroupCompletedPrimary ImmunodeficiencyUnited States
-
Baxalta now part of ShireCompletedImmune Thrombocytopenic Purpura (ITP)Poland, Hungary, Germany, Czechia
-
Biopharma Plasma LLCRecruitingPrimary Immune ThrombocytopeniaUkraine
-
Baxalta now part of ShireCompletedPrimary Immunodeficiency Diseases (PID)United States
-
Baxalta now part of ShireCompletedPrimary Immunodeficiency Diseases (PID)Japan